Published 18 hours ago • loading... • Updated 18 hours agoShow Less IconAbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? Summary by The Motley FoolAbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.Share menu1 Articles1 ArticlesAllLeft1CenterRightSearch IconSort IconThe Motley FoolLean LeftFactualityOwnershipAbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.18 hours ago·Alexandria, United StatesRead Full ArticleThink freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribeBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsCoverage DetailsTotal News Sources1Leaning Left1Leaning Right0Center0Last Updated17 hours agoBias Distribution100% LeftBias Distribution Too Big Arrow IconToo Big Arrow IconCaret Up Icon100% of the sources lean Left100% LeftL 100%Factuality Info IconTo view factuality data please Upgrade to PremiumOwnership Info IconTo view ownership data please Upgrade to VantageThe Motley Fool broke the news in Alexandria, United States 18 hours ago on Thursday, October 1, 2026.Too Big Arrow IconCaret Down IconSources are mostly out of (0)Similar News TopicsAbbVie Plus IconUnited States Plus IconShow AllBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsSimilar News TopicsAbbVie Plus IconUnited States Plus IconShow All